About Us - Aurelius Biotherapeutics

Our Story

Our beginning started with a collaboration with the MD Anderson Cancer Center and a clinical study in dogs with naturally occurring B cell lymphoma. Soon after, we founded Aurelius Biotherapeutics to continue the original work. Together with our team of scientists, we have developed a potentially transformative treatment using living and individualized immunotherapies to treat this form of canine cancer.

Collaborations

We are committed to continuing to develop T cell therapies and explore their broad potential. Our collaborations include:

Fred Hutchinson

MD Anderson

Lytix

Our work is supported in part by The Perseus Foundation, The Bob and Rebecca Pohlad Family Foundation, Nina and Darrell Hallet, and many other generous donors, too numerous to list.

Our Team

Aurelius Biotherapeutics is a privately held LLC operating in the state of Washington.

Board

Theresa Westfall DVM, CEO
Edmund Sullivan DVM, CSO
James Gibson CPA, CFO
Kevin Steele, Ph.D. Immunology

Recent Articles

Collaboration with Lytix Biopharma

A new first-in-class therapy for canine lymphoma is being developed by a collaboration between Aurelius Biotherapeutics and Lytix Biopharma a human immunotherapy development company. The two companies realized they were a good fit when the CEO’s met at the SITC...

T-Cell Therapy in Cancer Treatment

For many years, we have treated cancer with surgery, chemotherapy, and radiation therapy. But lately, immunotherapy—treatment that uses the patient's own immune system—has grown in importance. Adoptive Cell Transfer (ACT) is a therapy that collects and uses patient's...

Canine Lymphoma: Adoptive T Cell Protocol

Adoptive T Cell Therapy can be an effective tool for treating canine lymphoma. Here is what you can expect if you choose to use adoptive T cell therapy for your dog. Your veterinarian will collect and send a simple blood sample from your dog- it is shipped overnight...